

## **OrthoPediatrics Corp.** June 2020

## Mark Throdahl, CEO Fred Hite, CFO



#### **Forward-Looking Statements**

This presentation includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," "predict," "intend," "future," "goals," "potential," "objective," "would" and other similar expressions. Forward-looking statements involve risks and uncertainties, many of which are beyond OrthoPediatrics' control. Important factors could cause actual results to differ materially from those in the forward-looking statements, including, among others: the risks related to COVID-19, the impact such pandemic may have on the demand for our products, and our ability to respond to the related challenges; and the risks, uncertainties and factors set forth under "Risk Factors" in OrthoPediatrics' Annual Report on Form 10-K filed with the SEC on March 5, 2020, as updated and supplemented by our other SEC reports filed time to time. Forward-looking statements speak only as of the date they are made. OrthoPediatrics assumes no obligation to update forward-looking statements to reflect actual results, subsequent events, or circumstances or other changes affecting such statements except to the extent required by applicable securities laws.

#### **Use of Non-GAAP Financial Measures**

This presentation includes the non-GAAP financial measure of Adjusted EBITDA, which differs from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). Adjusted EBITDA in this release represents net loss, plus interest expense, net plus other expense, depreciation and amortization, stock-based compensation expense, and acquisition related costs. Adjusted EBITDA is presented because the Company believes it is a useful indicator of its operating performance. Management uses the metric as a measure of the Company's operating performance and for planning purposes, including financial projections. The Company believes this measure is useful to investors as supplemental information because it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company believes Adjusted EBITDA is useful to its management and investors as a measure of comparative operating performance from period to period. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as an alternative to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company's future results will be unaffected by unusual or non-recurring items. In addition, the measure is not intended to be a measure of free cash flow for management's discretionary use, as it does not reflect certain cash requirements such as debt service requirements, capital expenditures and other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and other potential cash requirements. In evaluating Adjusted EBITDA, you should be aware that in the future the Company may incur expenses that are the same or similar to some of the adjustments in this presentation. The Company's presentation of Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company's GAAP results in addition to using Adjusted EBITDA on a supplemental basis. The Company's definition of this measure is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.



## Highlights

### Large Market

## **Proprietary Technology**

### **Scalable Business**

- Diversified medical device company focused exclusively on pediatric orthopedics
- Protected market opportunity: \$1.4 billion U.S., \$3.2 billion globally (2019 estimates)
- P High U.S. procedure concentration: <300 hospitals and ~1,400 surgeons
- **Focused call point: pediatric orthopedic surgeons are generalists who use all OP products**
- Sustainable competitive advantage:
  - Broadest pediatric-specific orthopedic product offering with 35 surgical systems
  - Strong relationships with pediatric orthopedic surgeons
  - Deep commitment to clinical education
  - Sales personnel are a consultative resource who attend surgery
- Consistent 20+% growth since inception
  - FY19 revenue of \$72.6 million, up 26%
- Recent Orthex and ApiFix acquisitions give OP proprietary, leading-edge technology in both external fixation and non-fusion scoliosis markets and expand the Company's total addressable market

## **COVID-19 Update**



Environment and Company Response

Impact on

**Financials** 

- Working closely with surgeon base, partners, and key suppliers; continuing to build inventories of critical products
- Accelerated sales training on new products including Orthex and recently acquire Apifix with remote learning
- Company implemented safety measures across the organization, including working remote since mid-March
- Currently committed to no lay-offs or base reduction salary cuts to all direct employees and established a Distributor Relief Fund for U.S. sales agencies
- Utilizing DocMatter website to sponsor webinars around pediatric orthopedic care in midst of COVID-19 pandemic
- Product development has not been affected and proceeds at normal pace
- 31% sales growth February 2020 YTD; 30 percent domestic sales growth for the first quarter 2020 offset by earlier impact in international markets (32% OUS decrease) for a net sales growth of 12%
  - Company withdrew its previously announced 2020 revenue growth and consignment set guidance of 22%-24% and \$19-\$21 million, respectively
  - Deformity Correction and Scoliosis businesses significantly impacted; April total sales down ~60%; began seeing improvements in May and June schedule filling up nicely
  - Anticipate 2Q20 revenues to be down ~30% overall, with domestic only down ~20%



## **OP Today**

5

## A Company Built on a CAUSE

#### Cause

Improving the lives of children with orthopedic conditions



Gideon with CMO Peter Armstrong, M.D., c. 1995. Gideon's drawing of his girlfriend, 2016.

#### **Company Snapshot**

- Treated >172,000 patients since inception
- 35 surgical systems; ~7,300 SKUs; strong pipeline
- **4** additional systems from Vilex and ApiFix acquisitions
- 103 direct employees; 167 focused sales reps<sup>1</sup>
- Global sales organization focused on pediatric orthopedic surgeons in 44 countries<sup>1</sup>
- 79 issued patents; 65 pending patents<sup>2</sup>
- Chief Medical Officer is a fellow surgeon
- Average FDA approval time: < 1/2 industry average
- P History of stable reimbursement

<sup>1</sup> As of March 31, 2020
 <sup>2</sup> As of March 31, 2020 and does <u>not</u> include Vilex/Orthex patents/patent applications




## **Our Key Idea**

## **Children Are Not Small Adults**

### **Superior Clinical Outcomes**






Screws Through Growth Plate Screws Parallel To Growth Plate

#### **OP's Market Impact**

- Address orthopedic industry's lack of focus on product development, clinical education, and sales presence
- Implants and instruments avoid complications of re-purposed adult products
- Product development in collaboration with leading pediatric orthopedic surgeons
- **Dedicated sales support attending surgeries**
- Clinical education programs that build brand loyalty






Current products target three of the largest categories in Pediatric Orthopedics Pipeline products underway to expand addressable market


<sup>1</sup>Management's 2019 updates to IMS data from 2016






- \$72.6 million sales in 2019, increasing 26%
- Well diversified product sales and sources of growth
- All major product families contributed to revenue growth
- **All products have comparable gross margins**

#### 2019 Revenue by Product Family



#### 2019 Revenue by Geography





## A Proven Strategy Since 2011





## New Systems & Product Launches (2017-2018)



Titanium PediPlates® System (Expands physeal tethering offering)



Clavicle Plate System (First pediatric specific system)



Wrist Fusion Plate System (First pediatric specific system)



PediFlex Advanced



Pediatric Nailing Platform | FEMUR (Expands into adolescent cases)





FIREFLY<sup>®</sup> Pedicle Screw Navigation Guides (Complementary to RESPONSE Spine System)



FireFly S2/Alar



RESPONSE 4.5/4.75/5.0mm System (Maximizes intraoperative flexibility)


Scoliosis



Medial Patella Femoral Ligament Reconstruction System (Complementary to ACL Reconstruction System)




## **New Systems & Upcoming Product Launches (2019-2020)**





## **Strong Pipeline**







#### **Smart Implants**

- Proof of concept established in 2018 with substantial development in 2019
- 2 embodiments: (1) scoliosis (2) intramedullary nailing
- OP will offer significant improvements to current technology




#### **Early Onset Scoliosis**

- Emerging surgical trends not being pursued by major spine companies
- Intervention in patients as young as 10
- **Reversible, non-fusion procedures**
- **Developing IP portfolio**
- **Working with panel of leading surgeons**



## **Global Sales Coverage**





Currently selling to major children's hospitals in the U.S. and 43 additional countries Converting to agency model in select markets has significantly increased volumes, ASPs, and gross margin Replicate success of sales agency model in UK, IRE, AUS, NZ, CAN, BE, NL, and IT

## **Vilex Acquisition**



### **Transaction Details**

- Acquisition: In June 2019 OP purchased Vilex<sup>1</sup> and its Orthex Hexapod<sup>2</sup> system with proprietary point-and-click planning software, for \$60 million (\$50 million cash + \$10 million shares)
- Divestiture: In December 2019 OP sold the adult assets and Orthex license for non-pediatrics market to Squadron Capital for \$25 million cash.
- Net: Orthex Hexapod investment of \$35 million

#### **Benefits**

- Expands OP's Trauma & Deformity business into new segment valued at \$200 million globally
- Expands Trauma & Deformity's breadth from 60% to 80% of addressable market
- Increases surgeon reach to limb reconstruction specialists who treat pediatric patients beyond children's hospitals, generating pull-through of other products
- Divestiture allows OP to remain committed solely to pediatrics with cross license rights





<sup>1</sup>Vilex generated \$6.7 million of revenue in 2018 (most of which was adult)

<sup>2</sup> Hexapod had 50% annual revenue growth since FDA clearance in mid-2016; generated \$5.1 million of revenue in 2018

## **Orthex Advantages**



#### **Disruptive Technology**

- **Construct allows 90° angulation** QP
- QP Unique calibrated structs and HA-coated pins
- QP Patented point and click software
- QP Significantly simplifies surgery planning and subsequent alignments 100

#### Dror Paley, MD – Pediatric orthopedic KOL

Introduced Ilizarov method in U.S. QP


#### Defend competitive position and risk

QP **Defend other potential acquirers from entering** the pediatric space





#### ML X-Ray



## **ApiFix Acquisition**




#### **Transaction Details**

Acquisition: In April 2020, OP purchased ApiFix<sup>1</sup> and its MID-C minimally invasive deformity correction system, for 934,768 shares of common stock and \$2 million in cash paid at closing, plus milestone payments and an earnout over a period of four years

#### **Benefits**


- Expands OP's Scoliosis business into non-fusion market, the holy grail of pediatric scoliosis surgery
- One of only two non-fusion technologies approved by the U.S. FDA and granted pediatric HDE
- Least invasive, removable system that acts as an internal brace with motion-preserving capabilities to avoids permanently limiting range of motion
- Measurable reductions in surgery time, blood loss, hospitalization, recovery time, and complication rates
- Extremely high sales/dollar of set inventory
- Strong IP protection: 46 granted patents and 25 patent applications







## ApiFix is a Viable Alternative to Failed Bracing and Spinal Fusion for the Treatment of Progressive Scoliosis






## Minimally Invasive Deformity Correction (MID-C) System for Scoliosis

- Viable alternative to failed bracing and spinal fusion with motion-preserving technique
  - Self-adjusting rod and novel polyaxial joints
  - Least invasive surgical solution
    - Placed posteriorly and unilaterally on the concave aspect of the curvature
    - No thoracic surgeon; no need to collapse the lung
- Removable (burns no bridges)
- Surgery time 1-2 hours; Incision size 10-15cm; Blood loss 50cc
- Post-surgery hospital stays of 1-2 days

   Patient recovery measured in days, not months
- Low complication and revision rates
- FDA and CE Mark approved procedure backed by clinical data on 370+ patients and long-term (8 year) data



## New Competitors Would Face Formidable Obstacles



"The ship has sailed."

- Product breadth
- **Surgeon relationships**
- Sales and distribution network
- **Clinical education programs**
- **Pediatric brand equity**
- Reputation with pediatric orthopedic societies
- **Dynamic culture**



## Surgeon relationships and clinical education

- Relationships with surgeons who use entire portfolio
- P Major provider of clinical education
- Leading supporter of surgical societies
- **Custom instruments**

## Robust organic growth opportunities

- \$3.2 billion addressable global market
- Limited focused competition
- Focused, experienced distribution
- Instrument set placements drive growth

# Broadest, most innovative product offering

- I3 years' clinical understanding
- New product pipeline
- Pediatric Market Gateway for distributed products and joint product developments

Leading Innovation in Pediatric Orthopedics

# Attractive growth and margin profile


- **Consistent growth since inception**
- **P** 75% gross margin in FY 2019
- P History of efficient capital utilization



## **Financial Review**











## **Category Revenue Summary**





### Seasonality Drives Stronger Performance in Summer Months and Holiday Periods





(\$ in Millions)	S. S					
	FY 2016	FY 2017	FY 2018	FY 2019	1Q 2019	1Q 2020
Revenue	\$37.3	\$45.6	\$57.6	\$72.6	\$14.7	\$16.3
Growth %	20%	22%	26%	26%	21%	11%
Gross Profit	\$26.4	\$34.5	\$42.7	\$54.6	\$10.7	\$12.1
Margin %	71%	76%	74%	75%	73%	75%
Operating Expenses	\$32.5	\$40.9	\$52.2	\$63.7	\$13.4	\$16.7
Operating Loss	(\$6.1)	(\$6.5)	(\$9.6)	(\$9.1)	(\$2.7)	(\$4.6)
Net Loss	(\$6.6)	(\$8.9)	(\$12.0)	(\$13.7)	(\$3.0)	(\$5.0)
Net Loss per Share <sup>1</sup>	(\$7.14)	(\$5.86)	(\$0.96)	(\$0.94)	(\$0.21)	(\$0.31)

<sup>1</sup> Net loss per share attributable to common stockholders – basic and diluted



		Three Months Ended March 31,		
	2019	2020		
Net loss	(\$3.0)	(\$5.0)		
Interest expense, net	0.3	0.4		
Other expense	-	0.1		
Depreciation and amortization	0.8	1.4		
Stock-based compensation	0.5	1.0		
Acquisition related costs	-	0.1		
Adjusted EBITDA	(\$1.4)	(\$2.2)		



#### (\$ in Millions) As of March 31, 2020

Assets	
Cash & Restricted Cash	\$54.9
Accounts receivable	14.0
Inventory (net)	44.0
Other current assets	2.1
PP&E (net)	24.1
Intangibles	35.0
Total Assets	\$174.1

Liabilities	
Accounts payable	\$8.3
Debt	21.2
Accrued expenses	3.0
All other liabilities	2.5
Paid-in capital	274.4
Accumulated deficit (net)	(135.2)
Total Liabilities / Equity	\$174.1





## Surgeon relationships and clinical education

Eeading Innovation in Pediatric Orthopedics

Robust organic growth opportunities

Attractive growth and margin profile

Broadest, most innovative product offering